[go: up one dir, main page]

MX2018010709A - Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. - Google Patents

Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.

Info

Publication number
MX2018010709A
MX2018010709A MX2018010709A MX2018010709A MX2018010709A MX 2018010709 A MX2018010709 A MX 2018010709A MX 2018010709 A MX2018010709 A MX 2018010709A MX 2018010709 A MX2018010709 A MX 2018010709A MX 2018010709 A MX2018010709 A MX 2018010709A
Authority
MX
Mexico
Prior art keywords
checkpoint inhibitor
oncolytic virus
cancer therapy
virus combined
combined
Prior art date
Application number
MX2018010709A
Other languages
English (en)
Inventor
Wick Wolfgang
Rommelaere Jean
DAHM Michael
Leuchs Barbara
Marchini Antonio
Angelova Assia
Jäger Dirk
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of MX2018010709A publication Critical patent/MX2018010709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica en la que se combina un inhibidor de punto de control con un virus oncolítico y el uso de dicha combinación para el tratamiento del cáncer.
MX2018010709A 2016-04-01 2017-03-22 Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. MX2018010709A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163555 2016-04-01
EP16020193.5A EP3225253A1 (en) 2016-04-01 2016-05-27 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
PCT/EP2017/056886 WO2017167626A1 (en) 2016-04-01 2017-03-22 Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
MX2018010709A true MX2018010709A (es) 2019-01-14

Family

ID=55650316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010709A MX2018010709A (es) 2016-04-01 2017-03-22 Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.

Country Status (16)

Country Link
US (2) US11027013B2 (es)
EP (1) EP3225253A1 (es)
JP (1) JP6689400B2 (es)
KR (1) KR102195055B1 (es)
CN (1) CN109069601B (es)
AU (1) AU2017242089B2 (es)
BR (1) BR112018069927A2 (es)
CA (1) CA3019634A1 (es)
CL (1) CL2018002793A1 (es)
EA (1) EA037354B1 (es)
IL (1) IL261554B (es)
LT (1) LT3436058T (es)
MX (1) MX2018010709A (es)
SG (1) SG11201807977XA (es)
WO (1) WO2017167626A1 (es)
ZA (1) ZA201805548B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018235944B2 (en) * 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
TW201900193A (zh) 2017-04-28 2019-01-01 美商默沙東藥廠 用於癌症治療之生物標記物
CN109022616B (zh) * 2018-07-25 2021-11-12 广州烨善生物科技有限公司 一种检测溶瘤病毒的探针及其应用
EP3657172A1 (en) 2018-11-22 2020-05-27 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample
CN113795512A (zh) * 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
CN113747947A (zh) * 2019-02-28 2021-12-03 沙塔克实验室有限公司 组合疗法
CA3152250A1 (en) * 2019-09-10 2021-03-18 Novocure Gmbh A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
CN115135386A (zh) * 2019-12-19 2022-09-30 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
CN111154806A (zh) * 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
WO2024207425A1 (en) * 2023-04-07 2024-10-10 Virogin Biotech (Shanghai) Ltd. Combination of recombinant oncolytic virus and checkpoint inhibitor for the treatment of cancer
WO2024216390A1 (en) * 2023-04-20 2024-10-24 University Health Network Methods to treat glioma in subjects with defined tumour microenvironment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
US7179456B2 (en) * 2003-04-30 2007-02-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of parvovirus for brain tumor therapy
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
ES2402138T3 (es) 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia
ES2639857T3 (es) 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
SMT202500126T1 (it) 2008-12-09 2025-05-12 Hoffmann La Roche Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
EP2266588A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Method for cancer therapy based on co-administration of a parovirus and a cytokine
EP2266587A1 (en) * 2009-06-04 2010-12-29 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oncolytic virotherapy for prevention of tumor recurrence
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
EP2397542A1 (en) 2010-06-17 2011-12-21 Deutsches Krebsforschungszentrum Modified parvovirus having enhanced anti-tumour efficacy
EP2404609A1 (en) * 2010-07-07 2012-01-11 Deutsches Krebsforschungszentrum Use of parvovirus for eliminating cancer stem cells (CSCs)
EP2535055A1 (en) * 2011-06-15 2012-12-19 Deutsches Krebsforschungszentrum Oncolytic virotherapy for therapy of bone cancer
US20130129678A1 (en) * 2011-11-17 2013-05-23 Zahari Raykov Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
EP2829284A1 (en) * 2013-07-22 2015-01-28 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
NZ725459A (en) * 2014-05-13 2023-04-28 Bavarian Nordic As Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
CN106999577B (zh) * 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
EP3108892A1 (en) * 2015-06-23 2016-12-28 Deutsches Krebsforschungszentrum Parvovirus formulation for treating tumors

Also Published As

Publication number Publication date
SG11201807977XA (en) 2018-10-30
JP6689400B2 (ja) 2020-04-28
WO2017167626A1 (en) 2017-10-05
KR20180127468A (ko) 2018-11-28
US20190117768A1 (en) 2019-04-25
US20210228714A1 (en) 2021-07-29
EP3225253A1 (en) 2017-10-04
EA037354B1 (ru) 2021-03-17
US11027013B2 (en) 2021-06-08
CL2018002793A1 (es) 2019-02-01
IL261554B (en) 2022-05-01
JP2019510769A (ja) 2019-04-18
EA201891679A1 (ru) 2019-04-30
US11964015B2 (en) 2024-04-23
KR102195055B1 (ko) 2020-12-24
CN109069601A (zh) 2018-12-21
AU2017242089B2 (en) 2019-08-15
LT3436058T (lt) 2020-02-10
BR112018069927A2 (pt) 2019-02-05
CN109069601B (zh) 2022-05-10
NZ745264A (en) 2020-10-30
ZA201805548B (en) 2019-11-27
IL261554A (en) 2018-10-31
CA3019634A1 (en) 2017-10-05
AU2017242089A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
IL282727A (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL272948B1 (en) enpp1 inhibitors and their use for cancer treatment
MX2022008868A (es) Tratamiento del cancer con tg02.
EP4302835A3 (en) Methods of treating ovarian cancer
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
IL270511A (en) Combination therapies using niraparib and pembrolizumab for treating cancer
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
MX2021000289A (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
MX373231B (es) Agente anticancerigeno.
IL285221A (en) Use of oncolytic viruses to treat cancer
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
SG11202103097QA (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.